Skandinaviska Enskilda Banken (SEB)
KPTI icon

Skandinaviska Enskilda Banken (SEB)’s Karyopharm Therapeutics KPTI Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,487
Closed -$706K – 1079
2020
Q2 		$706K Buy
+2,487
New +$736K 0.01% 772

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s KPTI Position: Q3 2020 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 2,487 shares — an estimated $706K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in KPTI in Q2 2020 and held it in 1 quarter. The position peaked at $706K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 2,487 Karyopharm Therapeutics shares in Q3 2020, an estimated $706K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Karyopharm Therapeutics position peaked at $706K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2020, filed 12 Nov 2020.